Skip to main content
. Author manuscript; available in PMC: 2010 Oct 21.
Published in final edited form as: Am J Kidney Dis. 1988 Feb;11(2):141–144. doi: 10.1016/s0272-6386(88)80199-9

Fig 1.

Fig 1

Actuarial graft survival in group 1 and group 2 patients treated with Orthoclone OKT3 compared with historical controls treated with high dose steroids and/or polyclonal ALG. Survival of group 2 grafts is significantly better than control and group 1 grafts (P < .01).